Non-exclusive drug discount agreement for Tapentadol
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tapentadol (ATC-Code nach WHO: N02AX06)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No minimum or guaranteed quantities; actual demand is uncertain and may be low.
The buyer may terminate open-house if exclusive agreements are concluded (typical after 8-12 months).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jul 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2027
- Non-exclusive discount agreement for Tapentadol (ATC N02AX06) film tablets
- Supply of pharmaceutical products under German statutory health insurance rebate system
Show full summary
This is a non-exclusive drug discount agreement (Rabattvereinbarung) under German law §130a Abs.8 SGB V for the active substance Tapentadol (ATC N02AX06) in film-coated tablet form. The procedure is an open-house model open to all qualified pharmaceutical companies. There is no exclusivity, no guaranteed minimum purchase quantities, and no estimated value provided. The contract runs until 31 July 2027. Submission is electronic via DTVP, and confidentiality of the tender documents is required.
Risks
No minimum or guaranteed quantities; actual demand is uncertain and may be low.
The buyer may terminate open-house if exclusive agreements are concluded (typical after 8-12 months).
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer) as defined in §4 Abs.18 AMG for the offered products
Eligibility
- Must submit declaration of no exclusion grounds (§§123,124 GWB)
Administrative
- Must submit declaration regarding EU sanctions against Russia (Regulation 833/2014)
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Tapentadol
Single lot for non-exclusive discount agreement for Tapentadol film tablets. Open to all qualified pharmaceutical companies. No guaranteed volumes.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tapentadol (ATC-Code nach WHO: N02AX06)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 29 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 349702-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No minimum or guaranteed quantities; actual demand is uncertain and may be low.
The buyer may terminate open-house if exclusive agreements are concluded (typical after 8-12 months).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications